Analyst Upgrades

• InterMune (ITMN) to outperform from neutral at RW Baird.
• Huntington Bancshares (HBAN) to buy from neutral at BofA/Merill.
• Halliburton (HAL), Cloud Peak Energy (CLD), Patriot Coal (PCX) and Consol Energy (CNX) to outperform from market perform at FBR Capital.
• Post Properties (PPS) to equal weight from underweight at Barclays.
• Airgas (ARG) to overweight from neutral at Piper Jaffray.
• Hologic (HOLX) to top pick from sector perform and Sunesis Pharma (SNSS) to outperform from sector perform at RBC Capital.

The U.S. House of Representatives passed the tax bill that had already been approved by the Senate, but that did little, if anything, to put a charge into the market today. Better-than-expected earnings reported after markets closed yesterday from Oracle and Research in Motion didn't boost the opening today either. Later in the morning, the report on leading economic indicators from the Conference Board also showed improvement, rising 0.4% in October. The dollar rose slightly on the forex market following Moody's five-notch downgrade of Irish debt. All in all, a day of mixed news with mixed results.

Here are the numbers for late afternoon trading today:

Dow Jones 11,491.98 -7.27 (-0.06%)
S&P 500 1,243.91 +1.04 (0.08%)
Nasdaq 2,642.97 +5.66 (0.21%)

On Tuesday, I outlined the nuts and bolts of a bullish call spread on InterMune (ITMN), with the speculator looking for the stock to rally as high as $75 prior to June expiration. Well, as many of you may have noticed, this trade isn't panning out too well -- yesterday, ITMN plummeted 75% after the Food and Drug Administration (FDA) unexpectedly rejected its experimental lung drug.

On the plus side, the long call spread trader's losses are inherently limited. Even with ITMN tumbling south of $10 per share on Wednesday, the worst that can happen is that both of his June-dated calls will expire worthless (which seems like a relatively safe bet at this point). The maximum potential loss on that spread amounts to no more than the initial net debit of $2.05 per pair of contracts.

Analyst Upgrades

• Citigroup upgraded Baker Hughes (BHI) to hold from sell following the company's Q1 results.
• Auriga upgraded Canadian Solar (CSIQ) to buy from hold as it believes the company's negative preannouncement on April 20 removes a downside catalyst. Despite upgrading, the firm lowered its target for shares to $21 from $25.
• Deutsche Bank upgraded Post Properties (PPS) to hold from sell following the company's Q1 results. The firm upped its target for shares to $27 from $16.
• Wright Express (WXS) was upgraded to buy from neutral at Goldman.
• Nvidia (NVDA) coverage was assumed with a buy from hold at ThinkEquity.
• Elan (ELN) was upgraded to neutral from sell at UBS.

InterMune (ITMN) has already racked up an impressive year-to-date gain of more than 268%, but one bullish bettor is expecting the equity's uptrend to continue during the near term. On Monday, a cautiously upbeat options trader singled out the drug stock for a long call spread.

Specifically, the speculator bought to open 1,000 contracts of InterMune's June 65 call, and simultaneously sold to open 1,000 contracts of the equity's June 75 call. The trader shelled out $3.53 for each June 65 call, and raked in $1.48 for the sale of each June 75 call. As a result, the long call spread was opened for a net debit of $2.05 per pair of contracts (which is why this strategy is often referred to as a "debit spread").

Analyst Upgrades

• Oppenheimer upgraded ConocoPhillips (COP) to outperform from perform after the company sold its stake in Syncrude. The firm has a $70 price target for shares.
• Leerink upgraded UnitedHealth (UNH) to outperform from market perform. The firm sees upside to the company's 2010 guidance and finds shares attractively valued at currently levels.
• Citigroup upgraded both Mirant (MIR) and RRI Energy (RRI) to hold from sell after the two companies agreed to merge.
• Cooper Companies (COO) was upgraded to outperform from market perform at FBR Capital.
• Expedia (EXPE) was upgraded to conviction buy from neutral at Goldman.
• A123 Systems (AONE) was upgraded to buy from hold at Deutsche Bank.

Late Tuesday, an advisory panel of the Food & Drug Administration (FDA) voiced its approval for pirfenidone, the experimental lung drug from InterMune (ITMN). The panel voted 9-3 in favor of recommending pirfenidone to patients with idiopathic pulmonary fibrosis.

The FDA is expected to follow the advice of the advisory panel, although it's not required to do so. The regulatory agency is due to issue its final ruling on the drug's fate by early May.

Analyst Upgrades

• ThinkEquity upgraded InterMune (ITMN) to buy from hold following the FDA advisory committee's approval of Esbriet. InterMune was also upgraded to outperform from market perform at Wells Fargo.
• Piper Jaffray upgraded Radian (RDN) to neutral from underweight with a $9 target. The firm believes the company will not have to raise capital as the government is allowing it to increase its leverage ratio beyond historic maximum levels.
• JPMorgan upgraded ExlService (EXLS) to neutral from underweight following the company's Q4 results.
• Lockheed Martin (LMT) was upgraded to neutral from underperform at Macquarie.
• Analog Devices (ADI) was upgraded to outperform from market perform at Bernstein.
• Goodrich (GR) was upgraded to conviction buy from buy at Goldman.

Analyst upgrades:

• Goldman said International Paper (NYSE: IP) is its top pick in the group citing leverage to early cycle containerboard. The firm upgraded shares to Conviction Buy from Buy and has a $26 target on the stock.
• Morgan Keegan upgraded Healthcare Realty Trust (NYSE: HR) to Outperform from Market Perform citing valuation and better-than-expected Q2 results.
• William Blair upgraded Harbin Electric (NASDAQ: HRBN) to Outperform from Market Perform as it believes the Chinese economy is likely to accelerate and the company's balance sheet is strengthened following the retirement of debt.
• Allstate (NYSE: ALL) was upgraded to Buy from Neutral at BofA/Merrill.
• VeriSign (NASDAQ: VRSN) was upgraded to Outperform from Neutral at Credit Suisse.
• Commercial Vehicle Group (NASDAQ: CVGI) was upgraded to Overweight from Underweight at JPMorgan.

Intermune (NASDAQ: ITMN) closed at $11.72. ITMN's Pirfenidone Capacity data is expected soon. ITMN February 12.5 straddle is priced at $7.40, April 12.5 straddle is at $9.80 and July 12.5 straddle is priced at $14.10 according to Track Data, suggesting large price movement.

Sequenom (NASDAQ: SQNM) closed at $23.09. SQNM will present Down's syndrome data after the market close today. SQNM February option implied volatility is at140; March is at 120; above its 26-week average of 103, according to Track Data, suggesting larger price movement.

Intermune (NASDAQ: ITMN) closed at $13.41. ITMN-191/R7128 combination data in January 2009. ITMN's Pirfenidone (inhibits collagen synthesis) data is expected in Q1 of 2009. Robert Baird has a Neutral rating on ITMN. ITMN January option implied volatility is at 189; April is at 175; above its 26-week average of 136 according to Track Data, suggesting larger price movement.

Onyx Pharma (NASDAQ: ONXX), a developer of cancer therapies, closed at $30.09. ONXX was raised to Overweight verses Neutral at JPMorgan. ONXX January option implied volatility of 76 is above its 26-week average of 69 according to Track Data, suggesting larger price movement.

OSI Pharma (NASDAQ: OSIP), a developer of cancer therapies, closed at $33.16. OSIP January option implied volatility is at 78, July is at 60. OSIP average option implied volatility over the last 26-weeks is 67 according to Track Data, suggesting larger near term risk with less outer month risk.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Analyst upgrades:

• Wachovia upgraded shares of Exelon (NYSE: EXC) to Outperform from Market Perform to reflect the company's attractive nuclear fleets and strong operational track record.
  
• Jesup & Lamont upgraded Ormat Technologies Inc. (NYSE: ORA) to Buy from Hold on valuation and increasing visibility on near-term Products revenue.
  
• RBC Capital upgraded Memc Electronic (NYSE: WFR) to Outperform from Sector Perform on expectations of improved demand growth following the likely eight-year extension of the US solar tax credit program.
• AmBev (NYSE: ABV) was raised to Outperform from Neutral at Credit Suisse.
  
• AmerisourceBergen (NYSE: ABC) was upgraded at Merrill Lynch to Buy from Neutral.
  
• Piper upgraded Anadys Pharma (NASDAQ: ANDS) to Neutral from Sell.

Analyst downgrades: